Scrutiny of Generic Drugmaker Inspections Tops OIG Agenda

The HHS Office of Inspector General (OIG) this year plans to analyze the findings from FDA inspections of generic drugmakers’ facilities to determine the effectiveness of inspections on ensuring the quality of generic medicines.
Drug GMP Report